Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I trial of neuroprotective therapies for the treatment of neurological conditions caused by chemotherapy

Trial Profile

A Phase I trial of neuroprotective therapies for the treatment of neurological conditions caused by chemotherapy

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Neuroprotectants (Primary)
  • Indications Neurodegenerative disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Sep 2018 I have assumed subjects to be healthy volunteers since this is a phase I trial. The trial may be carried out in patients. Please update the information when more details become available.Indications are taken from RDI profile.
    • 12 Sep 2018 New trial record
    • 27 Aug 2018 According to a Magnolia Neurosciences Corporation media release, the company expects to initiate this trial in the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top